Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Company profile
Ticker
VRTX
Exchange
Website
CEO
Jeffrey Leiden
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vertex Pharmaceuticals (San Diego) LLC • Vertex Pharmaceuticals (Distribution) Incorporated • Vertex Pharmaceuticals (Cayman) Limited • Vertex Pharmaceuticals (Cayman III) Limited • Vertex Pharmaceuticals (Cayman 509) Limited • Vertex Pharmaceuticals (Cayman 765) Limited • Vertex Pharmaceuticals (Cayman 787) Limited • Vertex Pharmaceuticals (Delaware) LLC • Vertex Pharmaceuticals (Puerto Rico) LLC • Vertex Pharmaceuticals (Canada) Incorporated ...
IRS number
43039129
VRTX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Feb 24
8-K
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
5 Feb 24
8-K
Other Events
8 Dec 23
8-K
Departure of Directors or Certain Officers
5 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Vertex Reports Third Quarter 2023 Financial Results
6 Nov 23
8-K
Departure of Directors or Certain Officers
5 Oct 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Vertex Reports Second Quarter 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
18 May 23
Transcripts
VRTX
Earnings call transcript
2023 Q4
5 Feb 24
VRTX
Earnings call transcript
2023 Q3
6 Nov 23
VRTX
Earnings call transcript
2023 Q2
1 Aug 23
VRTX
Earnings call transcript
2023 Q1
1 May 23
VRTX
Earnings call transcript
2022 Q4
7 Feb 23
VRTX
Earnings call transcript
2022 Q3
28 Oct 22
VRTX
Earnings call transcript
2022 Q2
5 Aug 22
VRTX
Earnings call transcript
2022 Q1
6 May 22
VRTX
Earnings call transcript
2021 Q4
27 Jan 22
VRTX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
CHARLES F WAGNER JR
27 Feb 24
4
Ourania Tatsis
27 Feb 24
4
Amit Sachdev
27 Feb 24
4
Reshma Kewalramani
27 Feb 24
4
Carmen Bozic
27 Feb 24
4
Edward Morrow Atkinson III
27 Feb 24
4
Stuart A Arbuckle
27 Feb 24
4
Kristen Ambrose
27 Feb 24
4
DAVID ALTSHULER
27 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
66.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1151 |
Opened positions | 196 |
Closed positions | 282 |
Increased positions | 447 |
Reduced positions | 374 |
13F shares | Current |
---|---|
Total value | 62.07 tn |
Total shares | 170.72 mm |
Total puts | 582.54 k |
Total calls | 520.56 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 22.28 mm | $9.07 tn |
Capital World Investors | 21.81 mm | $8.87 tn |
FMR | 12.98 mm | $5.28 tn |
STT State Street | 12.08 mm | $4.92 tn |
T. Rowe Price | 5.89 mm | $2.40 bn |
JPM JPMorgan Chase & Co. | 5.62 mm | $2.29 tn |
Wellington Management | 5.23 mm | $2.13 tn |
Jennison Associates | 3.94 mm | $1.61 tn |
Massachusetts Financial Services | 3.63 mm | $1.48 tn |
Capital Research Global Investors | 3.57 mm | $1.45 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Tatsis Ourania | Common Stock | Sell | Dispose S | No | Yes | 425.7 | 354 | 150.70 k | 55,804 |
26 Feb 24 | Amit Sachdev | Common Stock | Sell | Dispose S | No | Yes | 425.7 | 3,004 | 1.28 mm | 55,325 |
23 Feb 24 | Wagner Charles F JR | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 3,309 | 1.43 mm | 53,583 |
23 Feb 24 | Tatsis Ourania | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 3,309 | 1.43 mm | 56,158 |
23 Feb 24 | Amit Sachdev | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 2,469 | 1.07 mm | 58,329 |
23 Feb 24 | Kewalramani Reshma | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 9,386 | 4.05 mm | 136,507 |
23 Feb 24 | Bozic Carmen | Common Stock | Payment of exercise | Dispose F | No | No | 431.79 | 3,309 | 1.43 mm | 36,939 |
News
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
8 Mar 24
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
1 Mar 24
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today
27 Feb 24
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
26 Feb 24
What Analysts Are Saying About Vertex Pharmaceuticals Stock
20 Feb 24
Press releases
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
13 Feb 24
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
5 Feb 24
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
5 Feb 24
Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?
5 Feb 24
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
30 Jan 24